358 related articles for article (PubMed ID: 25544671)
21. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
22. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
Pietrantonio F; Caporale M; Morano F; Scartozzi M; Gloghini A; De Vita F; Giommoni E; Fornaro L; Aprile G; Melisi D; Berenato R; Mennitto A; Volpi CC; Laterza MM; Pusceddu V; Antonuzzo L; Vasile E; Ongaro E; Simionato F; de Braud F; Torri V; Di Bartolomeo M
Int J Cancer; 2016 Dec; 139(12):2859-2864. PubMed ID: 27578417
[TBL] [Abstract][Full Text] [Related]
23. Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival.
Subasinghe D; Sivaganesh S; Samarsekera A; Kumarasinghe MP; Samarasekera DN; Lokuhetty MDS
Dig Dis Sci; 2017 Sep; 62(9):2498-2510. PubMed ID: 28612195
[TBL] [Abstract][Full Text] [Related]
24. Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions.
Kim H; Son SM; Woo CG; Lee OJ; Kim DH; Yun HY; Yun J; Kim HK; Yang Y; Han HS
BMC Cancer; 2019 Sep; 19(1):834. PubMed ID: 31477048
[TBL] [Abstract][Full Text] [Related]
25. HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study.
Kim WH; Gomez-Izquierdo L; Vilardell F; Chu KM; Soucy G; Dos Santos LV; Monges G; Viale G; Brito MJ; Osborne S; Noé J; Du X
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):239-245. PubMed ID: 27490762
[TBL] [Abstract][Full Text] [Related]
26. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
27. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
[TBL] [Abstract][Full Text] [Related]
28. Human epidermal growth factor receptor 2 overexpression in gastric and gastroesophageal junction adenocarcinoma in patients seen at the University Teaching Hospital, Lusaka, Zambia.
Kasochi C; Julius P; Mweemba I; Kayamba V
Afr Health Sci; 2020 Dec; 20(4):1857-1864. PubMed ID: 34394249
[TBL] [Abstract][Full Text] [Related]
29. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
30. Human epidermal growth factor receptor 2 expression in gastric carcinoma and its association with histopathological parameters in Indian population.
Gupta P; Rao S; Bhalla S
Indian J Cancer; 2016; 53(4):505-511. PubMed ID: 28485339
[TBL] [Abstract][Full Text] [Related]
31. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE; Meeuwissen H; Methorst N
Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
[TBL] [Abstract][Full Text] [Related]
32. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
33. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257
[TBL] [Abstract][Full Text] [Related]
34. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.
Baykara M; Benekli M; Ekinci O; Irkkan SC; Karaca H; Demirci U; Akinci MB; Unal OU; Dane F; Turkoz FP; Balakan O; Eser EP; Ozturk SC; Ozkan M; Oksuzoglu B; Sevinc A; Demir N; Harputluoglu H; Yalcin B; Coskun U; Uner A; Ozet A; Buyukberber S;
J Gastrointest Surg; 2015 Sep; 19(9):1565-71. PubMed ID: 26179664
[TBL] [Abstract][Full Text] [Related]
35. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB
Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718
[TBL] [Abstract][Full Text] [Related]
36. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
[TBL] [Abstract][Full Text] [Related]
37. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
Janjigian YY; Werner D; Pauligk C; Steinmetz K; Kelsen DP; Jäger E; Altmannsberger HM; Robinson E; Tafe LJ; Tang LH; Shah MA; Al-Batran SE
Ann Oncol; 2012 Oct; 23(10):2656-2662. PubMed ID: 22689179
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
[TBL] [Abstract][Full Text] [Related]
40. Two updates on oesophagogastric junction adenocarcinoma from the fifth WHO classification: Alteration of definition and emphasis on HER2 test.
Li Y; Li J; Li J
Histol Histopathol; 2021 Mar; 36(3):339-346. PubMed ID: 33377175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]